The Expanding Toolbox of In Vivo Bioluminescent Imaging

In vivo bioluminescent imaging (BLI) permits the visualization of engineered bioluminescence from living cells and tissues to provide a unique perspective toward the understanding of biological processes as they occur within the framework of an authentic in vivo environment. The toolbox of in vivo BLI includes an inventory of luciferase compounds capable of generating bioluminescent light signals along with sophisticated and powerful instrumentation designed to detect and quantify these light signals non-invasively as they emit from the living subject. The information acquired reveals the dynamics of a wide range of biological functions that play key roles in the physiological and pathological control of disease and its therapeutic management. This mini review provides an overview of the tools and applications central to the evolution of in vivo BLI as a core technology in the preclinical imaging disciplines.

Real-time toxicity and metabolic activity tracking of human cells exposed to Escherichia coli O157:H7 in a mixed consortia

Escherichia coli O157:H7 is a significant human pathogen that is continually responsible for sickness, and even death, on a worldwide scale. While the pathology of E. coli O157:H7 infection has been well studied, the effect of it's multiple resulting cytotoxic mechanisms on host metabolic activity has not been well characterized. To develop a more thorough understanding of these effects, several bioluminescence assays were evaluated for their ability to track both toxicity and host metabolic activity levels in real-time. The use of continuously autobioluminescent human cells was determined to be the most favorable method for tracking these metrics, as its self-sufficient autobioluminescent phenotype was unaffected by the presence of the infecting bacteria and its signal could be measured without cellular destruction. Using this approach, it was determined that infection with as few as 10 CFU of E. coli O157:H7 could elicit cytotoxic effects. Regardless of the initial infective dose, an impact on metabolic expression was not observed until bacterial populations reached levels between 5 × 10(5) and 1 × 10(6) (R(2) = 0.933), indicating that a critical bacterial infection level must be reached prior to the onset of cytotoxic effects. Supporting this hypothesis, it was found that cells displaying infection-mediated metabolic activity reductions could recover to wild type metabolic activity levels if the infecting bacteria were removed prior to cell death. These results indicate that rapid treatment of E. coli O157:H7 infection could serve to limit host metabolic impact and reduce overall host cell death.

Sound localization in subjects with impaired hearing. Spatial-discrimination and interaural-discrimination tests

In order to get a systematic picture of how various hearing impairments and neurologic disorders may affect sound localization, psychophysical spatial- and lateralization-discrimination measurements were performed on 140 subjects, including 69 with different types of hearing impairments, 32 with neurological diseases, and 39 with normal hearing. The quantities measured were: in the freefield, the horizontal minimum audible angle (MAA) at eight reference azimuths around the head and the vertical MAA straight ahead; with headphones, the just-noticeable difference (JND) in interaural time delay and the JND in interaural intensity difference. The standard stimulus was broadband (0.25-10 kHz), pulsed (1-sec), noise presented at a suprathreshold level for both ears (65-100 dB SPL). The results show that there exist characteristic impairments of sound localization in the different types of hearing impairments tested. On a general level, the results are consistent with the concept that the localization of sound relies on a decision made by the central auditory system based on a number of cues present in the acoustic signal at the two ears. The cues tested in our study are: 1) the interaural time difference, 2) the interaural intensity difference, and 3) the spectrum of the received signal at each ear. At a more specific level, the sound localization impairments found in conductive hearing losses are interpreted as bone-conduction effects, the results found in sensorineural hearing losses are interpreted as consequences of impaired or preserved spectral processing, the results in neurinomas are interpreted as impaired signal transmission in the auditory nerves, and the results of subjects with central involvements suggest that separate processors exist at some level in the central auditory system for the different localization cues. Finally, comments are made about the practical clinical significance of sound localization tests in the audiological and neurological evaluation of patients.